Open Access Peer-reviewed

Rifampin and Their Analogs: A Development of Antitubercular Drugs

Mohammad Asif
Department of pharmacy, GRD (PG) Institute of Management & Technology, Dehradun, India
World Journal of Organic Chemistry. 2013, 1(2), 14-19. DOI: 10.12691/wjoc-1-2-2
Published online: August 25, 2017

Abstract

There has been considerable interest in various analogues of antitubercular drugs particularly against multidrug and extensively drug resistant tuberculosis because mycobacterium species has developed resistant against available drugs. The currently used antitubercular also causes some serious toxic effects and also require long period of therapy for the treatment. Therefore, various new drugs and analogues of currently used antitubercular drugs were prepared with minimum side effects or effective against multidrug and extensively drug resistant strains of tuberculosis. In present review we discussed about brief introduction of tuberculosis followed the rifampicin and their analogues which are effective against tuberculosis.

Keywords:

multidrug resistance, mycobacterium, tuberculosis, rifanpicine, analogues
[1]  Asif, M., 2012. Study of clinically used and recently developed antimycobacterial agents. Orient Pharm Exp Med, 12: pp. 15-34.View Article
 
[2]  World Health Organization. Strategic framework to decrease the burden of TB/HIV documents WHO/CDS/TB. 2002; 296, WHO/HIVAIDS/2002, 2. Geneva, Switzerland: World Health Organization.
 
[3]  World Health Organisation, Tuberculosis, Fact Sheet No. 104, 2007. http:// www.who.int/mediacentre/factsheets/who104/en/index.html/.
 
[4]  WHO report 2008: The Stop TB Strategy, case reports, treatment outcomes and estimates of TB burden. http://www.who.int/tb/publications/global_report/2008/annex_3/en/index.html.
 
[5]  Asif, M., Siddiqui, A.A., Husain, A., 2012. Quinolone derivatives as antitubercular drugs. Med Chem Res, 22(3): 1029-1042.View Article
 
[6]  Kamal, A., Azeeza, S., Malik, M.S., Shaik, A.A., and Rao, M.V. 2008. Efforts Towards the Development of New Antitubercular Agents: Potential for Thiolactomycin Based Compounds. J Pharm Pharmaceut Sci, 11 (2): 56s-80s. PubMed
 
[7]  Nahid, P., Pai, M., and Hopewell, P.C. Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc 2006; 3: 103-10.View Article  PubMed
 
[8]  Nguyen, L., and Thompson, C.J., 2006. Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends Microbiol, 14: 304-12.View Article  PubMed
 
[9]  WHO, 2005. Global tuberculosis control-surveillance, planning, financing (Geneva: World Health Organization).
 
[10]  World Health Organization (WHO). Treatment of tuberculosis: guidelines for national programmes. 3rd edition. 2003. Geneva.
 
[11]  Tripathi, R.P., Tewari, N., Dwivedi, N., and Tiwari, V.K., 2005. Fighting tuberculosis: An old disease with new challenges. Med Res Rev., 25: 93-131.View Article  PubMed
 
[12]  Bastian, I., and Colebunders, R., 1999. Treatment and prevention of multidrug-resistant tuberculosis. Drugs, 58(4), 633-661.View Article  PubMed
 
[13]  Ahmad, Z., Sharma, S., Khuller, GK., Singh, P., Faujdar, J., and Katoch, VM. 2006. Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis. Inter J Antimicrob Agents, 28(6): pp. 543-544.View Article  PubMed
 
[14]  Aldrich, C. C., Bosshoff, H. I., and Remmel R. P., 2010. Antitubercular agents, In: Burger's Medicinal Chemistry, Drug Discovery and Development, vol. 7 Antiinfectives, Abraham, Understanding Tuberculosi-D. J. & Rotella, D. P. (Eds.), 7th ed., pp.713-812, Wiley, New York.
 
[15]  Management of MDR-TB. A field guide A companion document to Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402, WHO Library Cataloguing-in-Publication Data: World Health Organization, 2009.
 
[16]  Center for Disease Control. "Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs—Worldwide, 2000-2004". 2006, 55: 301-305.
 
[17]  Grosset, J. H., 1992. Treatment of tuberculosis in HIV infection. Tuber Lung Dis, 73: 378-383.View Article
 
[18]  Centers for Disease Control and Prevention. 1982. Adverse drug reactions among children treated for tuberculosis. M.M.W.R. Morb. Mortal. Wkly. Rep., 29: 589-591.
 
[19]  Cole, ST., and Alzari, P. M. 2007. Towards new tuberculosis drugs. Biochemical Society Transactions, 35(5): pp. 1321-1324.View Article  PubMed
 
[20]  Glickman, S. W., Rasiel, E. B., Hamilton, C. D., Kubataev, A., and Schulman, K. A., 2006. Medicine. A portfolio model of drug development for tuberculosis. Science, 311, 1246-1247.View Article  PubMed
 
[21]  Stahlmann R, Lode H. Toxicity of quinolones. Drugs, 1999, 58(Suppl. 2):37-42.View Article  PubMed
 
[22]  Rieder, H.L., Arnadottir T., Trebucq A, and Enarson, D.A., 2001. Tuberculosis treatment: dangerous regimens? Inter J Tuberculosis & Lung Diseases. 5: pp. 1-3. PubMed
 
[23]  Russell, D. G., 2001. Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol, 2: 569-577.View Article  PubMed
 
[24]  Smith, C. V., Sharma, V., and Sacchettini, J. C., 2004. TB drug discovery: Addressing issues of persistence and resistance. Tuberculosis, 84, 45-55.View Article
 
[25]  O'Brien, R. J., and Nunn, P. P. The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. Am J Respir Crit Care Med, 2001, 163, 1055-1058.View Article  PubMed
 
[26]  Paramasivan, C. N., Sulochana, S., Kubendiran, G., Venkatesan, P., and Mitchison, D. A. 2005. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 49: 627-631.View Article  PubMed
 
[27]  Somoskovi, A., Parsons, L. M., and Salfinger, M., 2001. The molecular basis of resistance to Isoniazid, Rifampin, and Pyrazinamide in Mycobacterium tuberculosis. Respir. Res., 2: 164-168.View Article  PubMed
 
[28]  Farr, B.F. Rifamycins. In, Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 5th ed. (Mandell, G.L., Bennett, J.E., and Dolin, R., eds.) Churchill Livingstone, Philadelphia, 2000, pp. 348-361.
 
[29]  Temple, M.E., Nahata, M.C. Rifapentine: its role in the treatment of tuberculosis. Annals of Pharmacotherapy, 1999, 33(11):1202-1210.View Article
 
[30]  Zhang, Y., 2004. Persistent and dormant tubercle bacilli and latent tuberculosis. Frontiers Bioscience, 1(9): pp. 1136-1156.View Article
 
[31]  Baciewicz, A.M., Self, T.H., and Bekemeyer, W.B., 1987. Update on rifampin drug interactions. Arch. Intern. Med., 147: 565-568.View Article  PubMed
 
[32]  Cauthen, G.M., Kilburn, J.O., Kelly, G.D., and Good, R.C. Resistance to anti-tuberculosis drugs in patients with and without prior treatment: survey of 31 state and large city laboratories, 1982-1986. Am. Rev. Respir. Dis., 1988, 137(suppl):260.
 
[33]  Wade, M. M., and Zhang, Y., 2004. Mechanism of drug resistance in Mycobacterium tuberculosis. Frontiers in Bioscience, 9(1), pp.975-994.View Article  PubMed
 
[34]  Zhang, Y., and Amzel, L M., 2002. Tuberculosis drug targets. Current Drug Targets, 3(2): pp. 131-154.View Article  PubMed
 
[35]  Zhang, Y., Post-Martens, K., and Denkin, S., 2006. New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discovery Today, 11(1): pp. 21-27.View Article
 
[36]  Tomioka, H., Namba, K., 2006. Development of antitubercular drugs: current status and future prospects, Kekkaku (Japanese Journal)., 81 (12): 753-774. PubMed
 
[37]  Zierski, M., and Bek, E., 1980. Side effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. Tubercle, 61(1): pp.41-49.View Article
 
[38]  Gray, M.A., 1997. Tuberculosis Drugs. Orthopaedic Nursing, 16(4): 64-69.View Article  PubMed
 
[39]  Gangadharam, P.R. Isoniazid, rifampin, and hepatotoxicity. Am. Rev. Respir. Dis., 1986, 133:963-965. PubMed
 
[40]  Warrington, R.J., Hogg, G.R., Paraskevas, F., and Tse, K.S., 1977. Insidious rifampin-associated renal failure with light-chain proteinuria. Arch. Intern. Med., 137: 927-930.View Article  PubMed
 
[41]  Zhang, Y., 2005. The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol, 45: 529-564.View Article  PubMed
 
[42]  Garay, S. M. 2004, In Tuberculosis, W. N. a. G. Rom, S.M., ed. (Philadelphia: Lippincott Williams & Wilkins), 345-394.
 
[43]  Gutierrez-Lugo M-T, Bewley CA. Natural Products, Small Molecules, and Genetics in Tuberculosis Drug Development. J. Med. Chem. 51(9), 2606-2612 (2008).View Article  PubMed
 
[44]  Janin, Y.L. 2007. Antituberculosis drugs: Ten years of research. Bioorg. Med. Chem. 15(7): 2479-2513.View Article  PubMed
 
[45]  Figueiredo, R., Moiteiro, C., Medeiros, M.A. et al., 2009. Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H37Rv, MDR and NRP Mycobacterium tuberculosis. Bioorg. Med. Chem. 17(2): 503-511.View Article  PubMed
 
[46]  Dickinson, J.M., and Mitchison, D. A., 1987. In vitro activity of new rifamycins against rifampicin-resistant M. Tuberculosis and mais-complex Mycobacteria. Tubercle, 68:183-193.View Article
 
[47]  Shoen, C. M., DeStefano, M. S., and Cynamon, M. H.2000. Durable cure for tuberculosis: rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection. Clin Infect Dis, 30 Suppl 3, S288-290.View Article  PubMed
 
[48]  Moghazeh, S. L., Pan, X. S., Arain, T. M., Stover, C. K., and Musser, J. M. Comparative antimycrobial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother, 1996, 40, 2655-2657. PubMed
 
[49]  Hidaka, T. 1999. Current status and perspectives on the development of rifamycin derivative antibiotics. Kekkaku, 74 (1): 53-61. PubMed
 
[50]  Velayati, A. A., Masjedi, M. R., Farnia, P., Tabarsi, P., Ghanavi, J., Ziazarifi, A. H., and Hoffner, S. E., 2009. Emergence of new forms of totally drug-resistant tuberculosis bacilli: Super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest, 136(2): pp.420-425.View Article  PubMed
 
[51]  Vinšová, J., and Krátký, M., 2010. Tuberculosis - The development of new MDR-TB drugs, In: Drug-Resistant Tuberculosis, Causes, Diagnosis and Treatments, Nguy, S. & K’ung, Z. (Eds.), pp.59-141, Nova Science Publishers, ISBN 978-1-60876-055-8, New York.
 
[52]  Berning, S.E., 2001. The role of fluoroquinolones in tuberculosis today, Drugs. 61: 9-18.View Article  PubMed
 
[53]  Pasquato KFM, Ferreira EI. An approach for the rational design of new antitubercular agents. Current Drug Targets. 2001, 2: 427-437.View Article
 
[54]  Katz, A. H.; Caufield, C. E. 2003: Structure-based design approaches to cell wall biosynthesis inhibitors. Curr. Pharm. Design. 9: 857-866.View Article  PubMed
 
[55]  Blanchard, J.S. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu. Rev. Biochem., 1996, 65:215-239.View Article  PubMed
 
[56]  Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., and Dye, C. 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med, 163, 1009-1021.View Article  PubMed
 
[57]  Espinal MA. The global situation of MDR-TB. Tuberculosis. 2003, 83: 44-51.View Article
 
[58]  Paramasivan, C. N., Sulochana, S., Kubendiran, G., Venkatesan, P., and Mitchison, D. A. 2005. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 49: 627-631.View Article  PubMed
 
[59]  Russell, D. G., 2001. Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol, 2: 569-577.View Article  PubMed
 
[60]  Smith, C. V., Sharma, V., and Sacchettini, J. C., 2004. TB drug discovery: Addressing issues of persistence and resistance. Tuberculosis, 84, 45-55.View Article
 
[61]  Sunduru, N., Sharma, M., and Chauhan P.M.S., 2010. Recent advances in the design and synthesis of Heterocycles as anti-tubercular agents. Future Med Chem, 2(9): 1469-1500.View Article  PubMed